Lista de obras - Dirk Beher - Dominio Público Uruguay

3-Substituted gem-cyclohexane sulfone based gamma-secretase inhibitors for Alzheimer's disease: conformational analysis and biological activity.

artículo científico publicado en 2006

Alzheimer's disease mutations in APP but not γ-secretase modulators affect epsilon-cleavage-dependent AICD production

artículo científico publicado en 2013

Apoptosis in T cell acute lymphoblastic leukemia cells after cell cycle arrest induced by pharmacological inhibition of notch signaling.

artículo científico publicado en 2007

C-terminal PAL motif of presenilin and presenilin homologues required for normal active site conformation

artículo científico publicado en 2005

Cyclic sulfamide gamma-secretase inhibitors.

artículo científico publicado en 2005

Design and synthesis of highly potent benzodiazepine gamma-secretase inhibitors: preparation of (2S,3R)-3-(3,4-difluorophenyl)-2-(4-fluorophenyl)-4- hydroxy-N-((3S)-1-methyl-2-oxo-5- phenyl-2,3-dihydro-1H-benzo[e][1,4]-diazepin-3-yl)butyramide by us

artículo científico publicado en 2003

Development and characterization of a novel membrane assay for full-length BACE-1 at pH 6.0.

artículo científico publicado en 2012

Discovery of γ-secretase modulators with a novel activity profile by text-based virtual screening.

artículo científico publicado en 2012

Disrupted in Schizophrenia 1 and Nudel form a neurodevelopmentally regulated protein complex: implications for schizophrenia and other major neurological disorders

artículo científico publicado en 2004

Fatty acids increase presenilin-1 levels and [gamma]-secretase activity in PSwt-1 cells.

artículo científico publicado en 2004

Gamma-secretase as a therapeutic target for the treatment of Alzheimer's disease.

artículo científico publicado en 2005

Gamma-secretase complex assembly within the early secretory pathway

artículo científico publicado en 2005

Gamma-secretase modulation and its promise for Alzheimer's disease: a rationale for drug discovery.

scientific article published on January 2008

Generation and characterization of a rabbit monoclonal antibody site-specific for tau O-GlcNAcylated at serine 400

scientific article published on 07 October 2013

Generation of C-terminally truncated amyloid-beta peptides is dependent on gamma-secretase activity.

artículo científico publicado en 2002

Homodimerization of amyloid precursor protein and its implication in the amyloidogenic pathway of Alzheimer's disease.

artículo científico publicado en 2001

In vitro characterization of the presenilin-dependent gamma-secretase complex using a novel affinity ligand.

artículo científico publicado en 2003

LRRTM3 promotes processing of amyloid-precursor protein by BACE1 and is a positional candidate gene for late-onset Alzheimer's disease

artículo científico publicado en 2006

Molecular consequences of amyloid precursor protein and presenilin mutations causing autosomal-dominant Alzheimer's disease

artículo científico publicado en 2012

Novel non-carbohydrate O-GlcNAcase inhibitors with CNS drug properties as potential treatment for Alzheimer’s disease and tauopathies.

artículo científico publicado en 2013

Quantification of Alzheimer pathology in ageing and dementia: age-related accumulation of amyloid-beta(42) peptide in vascular dementia.

artículo científico publicado en 2006

Reactive oxygen species and Alzheimer's disease.

artículo científico publicado en 1997

Regulation of APP expression, biogenesis and metabolism by extracellular matrix and cytokines.

artículo científico publicado en 1996

Regulation of amyloid protein precursor (APP) binding to collagen and mapping of the binding sites on APP and collagen type I.

artículo científico publicado en 1996

Resveratrol is not a direct activator of SIRT1 enzyme activity

artículo científico publicado en 2009

Selected non-steroidal anti-inflammatory drugs and their derivatives target gamma-secretase at a novel site. Evidence for an allosteric mechanism.

artículo científico publicado en 2004

Selective modulation of Abeta42 production in Alzheimer's disease: non-steroidal anti-inflammatory drugs and beyond.

artículo científico publicado en 2006

Substrate determinants in the C99 juxtamembrane domains differentially affect γ-secretase cleavage specificity and modulator pharmacology.

artículo científico publicado en 2013

The amyloid precursor protein of Alzheimer's disease in the reduction of copper(II) to copper(I)

artículo científico publicado en 1996

The beta A4 amyloid precursor protein binding to copper.

artículo científico publicado en 1994

The role of γ-secretase activating protein (GSAP) and imatinib in the regulation of γ-secretase activity and amyloid-β generation

artículo científico publicado en 2012

gamma-Secretase as a target for drug intervention in Alzheimer's disease.

artículo científico publicado en 2004

gamma-Secretase cleavage site specificity differs for intracellular and secretory amyloid beta.

artículo científico publicado en 2003

gamma-Secretase inhibitors--from molecular probes to new therapeutics?

artículo científico publicado en 2003

Lista de obras de Dirk Beher

3-Substituted gem-cyclohexane sulfone based gamma-secretase inhibitors for Alzheimer's disease: conformational analysis and biological activity.

Alzheimer's disease mutations in APP but not γ-secretase modulators affect epsilon-cleavage-dependent AICD production

Apoptosis in T cell acute lymphoblastic leukemia cells after cell cycle arrest induced by pharmacological inhibition of notch signaling.

C-terminal PAL motif of presenilin and presenilin homologues required for normal active site conformation

Cyclic sulfamide gamma-secretase inhibitors.

Design and synthesis of highly potent benzodiazepine gamma-secretase inhibitors: preparation of (2S,3R)-3-(3,4-difluorophenyl)-2-(4-fluorophenyl)-4- hydroxy-N-((3S)-1-methyl-2-oxo-5- phenyl-2,3-dihydro-1H-benzo[e][1,4]-diazepin-3-yl)butyramide by us

Development and characterization of a novel membrane assay for full-length BACE-1 at pH 6.0.

Discovery of γ-secretase modulators with a novel activity profile by text-based virtual screening.

Disrupted in Schizophrenia 1 and Nudel form a neurodevelopmentally regulated protein complex: implications for schizophrenia and other major neurological disorders

Fatty acids increase presenilin-1 levels and [gamma]-secretase activity in PSwt-1 cells.

Gamma-secretase as a therapeutic target for the treatment of Alzheimer's disease.

Gamma-secretase complex assembly within the early secretory pathway

Gamma-secretase modulation and its promise for Alzheimer's disease: a rationale for drug discovery.

Generation and characterization of a rabbit monoclonal antibody site-specific for tau O-GlcNAcylated at serine 400

Generation of C-terminally truncated amyloid-beta peptides is dependent on gamma-secretase activity.

Homodimerization of amyloid precursor protein and its implication in the amyloidogenic pathway of Alzheimer's disease.

In vitro characterization of the presenilin-dependent gamma-secretase complex using a novel affinity ligand.

LRRTM3 promotes processing of amyloid-precursor protein by BACE1 and is a positional candidate gene for late-onset Alzheimer's disease

Molecular consequences of amyloid precursor protein and presenilin mutations causing autosomal-dominant Alzheimer's disease

Novel non-carbohydrate O-GlcNAcase inhibitors with CNS drug properties as potential treatment for Alzheimer’s disease and tauopathies.

Quantification of Alzheimer pathology in ageing and dementia: age-related accumulation of amyloid-beta(42) peptide in vascular dementia.

Reactive oxygen species and Alzheimer's disease.

Regulation of APP expression, biogenesis and metabolism by extracellular matrix and cytokines.

Regulation of amyloid protein precursor (APP) binding to collagen and mapping of the binding sites on APP and collagen type I.

Resveratrol is not a direct activator of SIRT1 enzyme activity

Selected non-steroidal anti-inflammatory drugs and their derivatives target gamma-secretase at a novel site. Evidence for an allosteric mechanism.

Selective modulation of Abeta42 production in Alzheimer's disease: non-steroidal anti-inflammatory drugs and beyond.

Substrate determinants in the C99 juxtamembrane domains differentially affect γ-secretase cleavage specificity and modulator pharmacology.

The amyloid precursor protein of Alzheimer's disease in the reduction of copper(II) to copper(I)

The beta A4 amyloid precursor protein binding to copper.

The role of γ-secretase activating protein (GSAP) and imatinib in the regulation of γ-secretase activity and amyloid-β generation

gamma-Secretase as a target for drug intervention in Alzheimer's disease.

gamma-Secretase cleavage site specificity differs for intracellular and secretory amyloid beta.

gamma-Secretase inhibitors--from molecular probes to new therapeutics?